Vedolizumab (2) (Entyvio®) – Antibiotic-refractory pouchitis, pre-treated patients

Characteristics

Start date 01.03.2022
Resolution 01.09.2022
INN Vedolizumab
Brand name Entyvio®
Pharm. company Takeda GmbH
G-BA procedure ID 2022-03-01-D-802
Therapeutic area Digestive system diseases
Reason for procedure New Indication

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Entyvio is indicated for the treatment of adult patients with moderate to severe active chronic pouchitis who have undergone proctocolectomy with the creation of an ileoanal pouch for ulcerative colitis (UC) and have had an inadequate response or no response to antibiotic treatment.

Subpopulation Indication Comparator
Adults with moderate to severe active chronic pouchitis who have undergone proctocolectomy for ulcerative colitis (UC) with the creation of an ileoanal pouch and have had an inadequate response or no response to antibiotic treatment. Treatment according to physician's choice

9. Associated procedures



<< List of all resolutions